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Abstract
Higher intakes of the omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
relative to the omega-6 arachidonic acid (AA) have been variably associated with reduced risk of 
premenopausal breast cancer. The purpose of this pilot trial was to assess feasibility and explore 
effects of high dose EPA and DHA on blood and benign breast tissue risk biomarkers prior to 
design of a placebo controlled Phase IIB trial. Premenopausal women with evidence of 
hyperplasia +/- atypia by baseline random periareolar fine needle aspiration (RPFNA) were given 
1860 mg of EPA + 1500 mg of DHA ethyl esters daily for 6 months. Blood and benign breast 
tissue were sampled during the same menstrual cycle phase pre-study and a median of 3 weeks 
after last dose. Additional blood was obtained within 24 hours of last dose. Feasibility which was 
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pre-defined as 50% uptake, 85% retention and 70% compliance, was demonstrated with 46% 
uptake, 94% completion, and 85% compliance. Cytologic atypia decreased from 77 to 38% 
(p=0.002), and Ki-67 from a median of 2.1 to 1.0 % (p=0.021) with an increase in the ratio of EPA 
+ DHA to AA in erythrocyte phospholipids but no change in blood hormones, adipokines, or 
cytokines. Exploratory breast proteomics assessment showed decreases in several proteins 
involved in hormone and cytokine signaling with mixed effects on those in the AKT/mTOR 
pathways. Further investigation of EPA plus DHA for breast cancer prevention in a placebo 
controlled trial in premenopausal women is warranted.
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Introduction
In addition to hormonal influences, cytokine production and chronic inflammation are 
increasingly being recognized as important in breast carcinogenesis [1]. A low level of 
macrophages which function to clear apoptotic cells are present in normal breast tissue; but 
a progressive increase in activated macrophages in inflammatory infiltrates has been 
observed in proliferative breast disease, DCIS and invasive breast cancer [2].
The initial stimulus for the increase in inflammatory cell infiltration might include 
immunogenic gene alterations in pre-cancerous epithelial cells [3] or abnormal adipocytes in 
obese women [4]; but the ratio of the long chain omega-3 to omega 6 fatty acids plays an 
important role in the continuation of the inflammatory process. Pro-inflammatory 
eicosanoids derived from the omega-6 fatty acid arachidonic acid (AA) released from 
activated macrophage membranes promote production of cytokines, proteases, pro-
angiogenic factors, and further macrophage infiltration [5]. The inflammatory loop can be 
interrupted with the long chain omega-3 fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) which compete with AA as substrate for cyclooxygenase and 
lipoxygenase enzymes and give rise to inflammation resolving metabolites [6]. However, 
continued excess of AA relative to the sum of EPA plus DHA, the norm in western diets, 
promotes chronic inflammation, and in pre-clinical models breast carcinogenesis [6-9]. The 
current intake of EPA and DHA in the US averages only 0.1-0.2% of calories with a total 
omega-3 to omega-6 intake ratio of ~ 1:10 [10]. Two case control studies using dietary 
recall instruments suggest breast cancer risk reduction in premenopausal women with higher 
intakes of omega-3 fatty acids [11,12]. It is likely to be easier to increase EPA and DHA 
from fish oil supplements than reduce omega-6 and AA in the diet frequently found in 
soybean, corn oil, meat, and eggs [13]. Rodent studies showing reduced mammary cancer 
incidence and multiplicity are generally with EPA plus DHA at 8-25% of calories or 
>1:1ratio of omega 3:6 ratio in feed [14,15].
There are multiple potential molecular mechanisms underlying the reduction in breast 
carcinogenesis in pre-clinical models with EPA and DHA supplementation [9]. The most 
important are likely to be reductions in NFκB and protein kinase c (PKC) activation, nuclear 
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translocation and signaling [16] with downstream reductions in cyclin D-1 and bcl2 [15], 
and disruption of cell membrane lipid rafts with reduced interaction potential of multiple 
oncogenic proteins including EGFR, SRC, and HER-2 [9,17-19]. Recent studies suggest that 
the actual levels of some of these proteins may also be reduced resulting from new 
juxtaposition to lysosomes and proteasomes [18]. Additional mechanisms include reduced 
adhesion molecule expression and motility and improved insulin sensitivity [20,21]. A sum 
result is likely reduction in proliferation, increased apoptosis, and reduced mammary 
carcinogenesis [18,19,22].
We conducted a study of blood and tissue fatty acid levels in a high risk cohort [23], and 
found that lower levels of omega-3 fatty acids were associated with evidence of cytologic 
atypia, a known risk predictor for development of breast cancer [24]. Given the lack of 
information in humans regarding the level of EPA and DHA supplementation which might 
be needed to favorably modulate risk biomarkers, we selected a dose of 3.4 grams per day of 
DHA + EPA ethyl esters, providing ~ 2% of calories. This dose is FDA approved for 
treatment of hypertriglyceridemia and is generally thought to be anti-inflammatory. 
Although this and higher doses are generally well tolerated, given the gastro-intestinal 
complaints in some women [25], a feasibility study assessing uptake, compliance, and 
effects on biomarkers was thought to be prudent prior to a randomized study. Since 
premenopausal but not postmenopausal women taking EPA and DHA have been reported to 
have increases in blood estradiol [26] and omega-3 fatty acids may impact progestin related 
EGF signaling [27], we conducted separate pilot studies of 6 months of EPA + DHA ethyl 
esters (4 g/day of Lovaza™) in pre- and post-menopausal women. Results of the study in 
premenopausal women are reported here.
Materials and Methods
Eligibility
Pre-menopausal women between the ages of 30 and 54 with no prior invasive breast cancer 
were potentially eligible for tissue screening by random periareolar fine needle aspiration 
(RPFNA) [24], provided they met risk criteria and had a stable hormone status for at least 6 
months. Women < 49 with intact ovaries but not menstruating had premenopausal status 
confirmed by FSH, estradiol, and progesterone. Stable hormonal status was defined as not 
stopping, starting, or significantly changing hormonal birth control within 6 months and no 
pregnancy or lactation within 12 months. Women over 40 were required to have a normal 
mammogram within 6 months prior to entering study.
Criteria for Breast Tissue Screening for Intervention
Risk criteria included any one or more of the following: a first degree relative or two or 
more affected second degree relatives under 60, a prior breast biopsy showing atypical 
hyperplasia or lobular carcinoma in situ, a prior contra-lateral treated breast cancer, a 5 year 
Gail model [28] risk ≥1.67% or a 10 year Tyrer-Cuzick (IBIS II) risk at least 2× that for age 
group > 50% mammographic breast density, RPFNA evidence of hyperplasia with atypia 
within the prior 3 years, or radiation to the neck or chest before the age of 30. Excluded 
were those who 1) had received tamoxifen or were on a clinical prevention study within the 
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prior 6 months, 2) had used fish oil or flaxseed supplements within 3 weeks prior to 
RPFNA, 3) regularly used NSAIDs, 4) had a BMI of 40 kg/m2 or higher, or 5) had breast 
implants.
Participants signed separate consents for IRB-approved protocols for screening and repeat 
RPFNAs (HSC 4601) and administration of Lovaza™ (HSC 12349; NCT01252277). 
Protocols were approved by the University of Kansas Medical Center Human Subjects 
Committee and were conducted in accordance with the Declaration of Helsinki. The first 
woman was enrolled January 2011 and the last completed the trial in March 2013.
Breast Tissue Biomarker Eligibility for Intervention
Women were required to have cytologic evidence of hyperplasia with atypia or borderline 
atypia (Masood score of 14 or higher) in specimens obtained by RPFNA [29]. Initially, 
women were not required to have evidence of Ki-67 expression but later selection criteria 
were tightened such that Ki-67 expression was required (the latter based on assessment of 
500 epithelial cells). We acquired 2-4 four vials of non-bloody frozen tissue for assessment 
of fatty acids, gene expression, adipocytokines, and proteomics.
Blood and Tissue Acquisition and Specimen Processing
Screening and off-study RPFNAs were performed between the first and tenth day after the 
onset of menses. For premenopausal women who were not regularly menstruating, follicular 
phase of cycle was confirmed by FSH, estradiol, and progesterone levels. For the RPFNA 
procedure, two sites per breast were aspirated under local anesthesia as previously described 
with needle tip preferentially guided to areas of increased resistance [24, 30]. One-fifth of 
the RPFNA material was immediately placed in 0.25 ml aliquots of phosphate buffered 
saline in cryovials, placed in liquid nitrogen and transferred to a −80° C freezer within 12 h 
until assessments for fatty acid analyses, adipocytokines (Luminex®), gene expression (RT-
qPCR), and proteomics. Remaining material was pooled in a single 15 cc tube with 9 ml 
CytoLyt® and 1 ml of 10% formalin (Hologic, Inc., Marlborough, MA) for cytomorphology 
and Ki- 67. Cells were pelleted, washed in CytoLyt® and transferred to PreservCyt®. 
Aliquots were then transferred to slides via ThinPrep® methodology for pap staining for 
cytomorphology or Ki-67.
Frozen RPFNA samples for each subject were quickly thawed in a cool water bath, 
transferred to ice, pooled and mixed. 250 μl of sample was removed and mixed with 750 μl 
Trizol® LS (Life Technologies, Grand Island, NY) and stored at −80° C until ready to 
extract RNA. Another 150-250 μl aliquot was transferred to a sterile 1.5 ml tube, quickly 
frozen in pulverized dry ice, and then stored at −80° C prior to Luminex® assays for 
adipocytokines. The remainder of the RPFNA sample on ice was briefly sonicated (Fisher 
100 Sonic Dismembrator) using three 10 sec pulses at low settings (≤10-15 W) and 
additional 250 μl aliquots were quick-frozen in dry ice and stored at −80° C for reverse 
phase proteomics and fatty acid analyses.
Fasting blood [30] was obtained at the on-study visit and at 6 months within 24 hours of 
scheduled drug discontinuation. Insulin, glucose, adipocytokines and fatty acid analyses 
were performed on fasting blood. A non-fasting sample was obtained with each RPFNA for 
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sex hormone binding globulin (SHBG) and hormones. Per protocol, the RPFNA was to be 
delayed 2 weeks after drug discontinuation to reduce chance of bruising. All biomarker 
assays except cytomorphology and Ki-67 were batch processed with samples stored in 
aliquots at −80° C so that pre- and post-intervention specimens were run together.
Cytomorphology
Cytomorphology was assessed by a single cytopathologist (CMZ) and classified by both a 
categorical method [24] and a semi-quantitative index score [29, 30]. The cytopathologist 
was aware that the subject was undergoing eligibility screening or off study aspiration but 
scoring of slides was performed without knowledge of prior score which was kept in the 
prevention lab data base. Scores of 12-14 generally correspond to hyperplasia and 15-18 to 
atypia [29]. The number of epithelial cells per slide was estimated and categorized in the 
following ranges: <10, 10-99, 100-499, 500-999, 1000-4999, or >5000.
Ki-67
Ki-67 assessment was performed after citrate buffer antigen retrieval, using a MIB-1 
monoclonal antibody (M7240; Dako Cytomation, Carpinteria, CA) at a 1:20 dilution with a 
Dako Autostainer Plus (Dako Cytomation). At baseline, only hyperplastic breast cell clusters 
were assessed, but at the 6-month follow-up, if no hyperplastic clusters were present, 
clusters containing the highest proportion of cells staining for Ki-67 were evaluated. 
Number of nuclear staining cells out of 500 cells was recorded by two independent readers 
without knowledge of prior Ki-67 until readings were complete. In case of a difference 
between the two readers, the scores were averaged [30].
Anthropometric and Dietary Variables
Height and weight were measured and a Dual Energy X-ray Absorptiometry or DEXA scan 
(Lunar Prodigy, GE Healthcare) was performed at baseline and post-intervention for body 
mass, fat mass, lean body mass, and android fat mass. Subjects completed the online 
National Cancer Institute Diet History Questionnaire II [31] pre- and post-intervention.
Mammographic Density
Pre- and post-intervention mammograms were all acquired on digital units at the University 
of Kansas Medical Center. A file was made of the cranial and caudal images of the left 
breast and images were coded and then de-identified by BFK for assessment by 2 readers 
(CJF and WLH) using Cumulus software [32]. Images were paired so that the reader was 
aware that they belonged to the same subject (but did not know which was pre-intervention 
and which post-intervention) as this is associated with reduced variability [32]. Images were 
assessed in batches of 14 including some sets multiple times such that variance could be 
assessed. The percent area of breast at increased density estimated by the two readers was 
averaged and used for analysis.
Adverse Events, Quality of Life, and Compliance
Adverse events were assessed monthly by the study coordinator and in the event of a 
significant symptom they were assessed by the protocol chair. Overall Quality of Life was 
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assessed pre- and post-intervention by the Breast Cancer Prevention Trial (BCPT) symptom 
scale as used previously [33].
High Dose Omega-3 Intervention
Women initiated the intervention within 6 months of their baseline RPFNA and took two 
capsules of Lovaza™ each containing 465 mg EPA and 375 mg DHA as the ethyl ester 
twice daily (total dose 3360 mg) with meals for a planned 6 months. Per protocol, the 
duration of the intervention could be modified for scheduling considerations.
Fatty Acid Analyses
Blood samples were collected in 5 ml sodium–EDTA tubes (BD Vacutainer, Franklin Lakes, 
NJ) and placed on ice immediately. Plasma and erythrocytes were separated by 
centrifugation (3000×g, 10 min; 4°C), frozen, and stored under nitrogen at −80° C until 
analysis. Lipids from plasma, erythrocytes, and breast tissue were isolated according to a 
modified Folch method [34], and fractionated by thin-layer chromatography. All lipid 
fractions were transmethylated with boron trifluoride-methanol, and the resulting fatty acid 
methyl esters (FAMEs) were separated using a Varian 3900 gas chromatograph with an 
SP-2560 capillary column (100 m, Sigma Aldrich) and a Star 6.41 Chromatography 
Workstation for peak integration and analysis [34]. Injector and detector temperatures were 
programmed at 260°C. The column temperature program for the 41-min column run was: 5 
min at 140°C; 4°C increase/min to 240° C; and 240° C, 11 min. Individual peaks were 
identified by comparison with qualitative standards (PUFA 1 and PUFA 2, Sigma Aldrich) 
and a weighed standard mixture (Supelco 37 Component FAME mix, Sigma Aldrich) was 
employed to adjust fatty acids for area/weight to calculate a final weight percent of total 
fatty acids.
Hormones and Growth Factors
Serum was frozen at −80°C in aliquots to avoid thawing and refreezing until assays were 
performed. Baseline and off-study samples were run together in batch assays, with control 
pooled sera included to assess inter and intra batch variation.
Serum assays performed in our laboratory were all ELISAs using commercially available 
kits from Diagnostics Biochem Canada Inc. (London, Ontario) except as noted. Estradiol 
(CAN-E430), testosterone (CAN-TE-250), and sex hormone binding globulin (SHBG; 
CAN-SHBG-410) results were used to calculate bioavailable estradiol and testosterone [29]. 
Progesterone (CAN-P-305) and high sensitivity C-reactive protein (CAN-CRP-4360) kits 
were also assayed. High molecular weight adiponectin (DHWAD0), insulin-like growth 
factor I (IGF-I; DG100), and insulin-like growth factor binding protein 3 (IGFBP-3; 
DGB300) kits were purchased from R&D Systems, Inc. (Minneapolis, MN).
Insulin was assessed by immunoassay and pro-insulin by immunochemoluminescent assay 
in the CLIA-approved clinical laboratories at the University of Kansas Hospital and Mayo 
Medical Laboratories respectively. Insulin resistance (IR), plus insulin sensitivity (%S) and 
beta cell function (%B) relative to normal young adults, was estimated from fasting glucose 
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and insulin levels using a calculator for the updated Homeostasis Model Assessment 
(HOMA2) [35], available from [36].
Serum and Tissue for Adipokine and Cytokine Assay by Luminex®
Frozen sera or RPFNA aspirates were utilized for adipokines and cytokine assessment using 
Milliplex® MAP Human Adipokine Magnetic Bead Panel 1 and Panel 2 kits from Millipore 
Corporation (Billerica, MA). Adipokines and cytokines assessed by Luminex® were 
adiponectin, leptin, macrophage chemoattractant factor 1 (MCP-1), tumor necrosis factor 
alpha (TNF-α), plasminogen activator inhibitor-1 (PAI-1), hepatocyte growth factor (HGF), 
nerve growth factor (NGF), resistin, and insulin. For tissue assays, results were normalized 
to total protein content (Bio-Rad Protein Assay, #500-0006, Bio-Rad Laboratories, Inc., 
Hercules, CA). For statistical analysis of changes in tissue, only 25 paired RPFNA samples 
were included where neither sample was visually bloody.
Tissue for RT-qPCR
Total RNA was extracted from frozen RPFNA samples using Trizol® LS (Life 
Technologies) according to the manufacturer's instructions. RNA was amplified using 
MessageAmp™II aRNA amplification kit (Life Technologies) and reverse transcribed to 
cDNA using SMARTScribe™ Reverse Transcriptase (Clontech Laboratories, Inc., 
Mountain View, CA) and random nonamer primers. Real-time PCR (qPCR) was performed 
using TaqMan chemistry as previously described [37]. Levels were expressed as relative to 
three reference transcripts (PPIA, PPIG, and HRPT1) using the δδCT method. For statistical 
analysis of changes, 25 paired specimens were included where neither was visually bloody. 
Genes assessed were ADIPOQ, LEP, ALOX15, ALOX15B, ALOX5, ALOX5AP, CD44, 
PTSG2, CCNB1, CCND1, ERP44, ESR1, SLC2A4, GREB1, HGF, HPGD, ICAM1, IGFBP2, 
KISS1, LTA4H, STK11, MCM2, CCL2, PPARG, PGR, TTF1, two splice variants for 
CXCL12, SDC1, TXNIP, VEGFA, XIAP; plus ACTB, GUSB, and B2M as potential reference 
transcripts that were eliminated when all data were analyzed by genormPLUS software 
(Biogazelle, Zwijnaarde, Belgium).
Tissue for Reverse Phase Protein Array (RPPA)
Frozen RPFNA specimens were utilized for RPPA performed at the CCSG Functional 
Proteomics Core at the University of Texas MD Anderson Cancer Center. Specimens were 
spotted onto a glass slide coated with nitrocellulose with each sample represented on the 
slide as a serial microdilution. Dilution series were replicated on spatially distant portions of 
the array. Each slide contained multiple positive and negative controls including quantitative 
peptide and phosphopetide controls with results normalized to total protein loading [38]. 
Pre- and post-intervention specimens were assessed together.
Assessment of 110 validated peptides and phosphopeptides was performed on 23 pairs of 
specimens, 16 of which were not visually bloody.
Statistical Analysis
The primary endpoint was feasibility defined as 50% or greater protocol acceptance in 
eligible women, with at least 85% retention and 70% compliance. The target accrual of 40 
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subjects was designed to provide paired (pre- and post-intervention) specimens for 
biomarker evaluation of at least 30 subjects. Secondary endpoints were a) change in risk 
biomarkers including cytomorphology, Ki-67, mammographic breast density, serum fasting 
insulin and pro-insulin, HOMA IR, HOMA %S, HOMA %B, IGF-1: IGFBP3, adiponectin 
and leptin and their ratio, BMI, change in body fat, % body fat distribution, and lean body 
mass; and b) change in fatty acid composition primarily in erythrocyte and breast tissue 
phospholipid compartments. Changes were also examined in molecular mechanism of action 
biomarkers including pro-inflammatory cytokines such as TNF-α, HGF, PAI-1; chemokines 
such as MCP-1; and proteins and phosphoproteins of interest in breast carcinogenesis. 
Adverse events and quality of life indices were studied as measures of safety and 
acceptability.
Data were summarized using frequencies and percentages for categorical variables, and 
medians, means and standard deviations for continuous variables.
Given the small sample sizes, non-parametric statistical analysis approaches were used 
throughout. Change in continuous biomarkers over the course of the intervention was 
assessed by the Wilcoxon signed rank test. For comparison of paired categorical variables 
(e.g., atypia), McNemar's test was used. All analyses were conducted using SPSS, version 
20 (IBM). A two-sided p-value <0.05 was considered as statistically significant. Since 
secondary analyses including biomarkers were considered exploratory, they were not 
corrected for multiple comparisons; rather, uncorrected p-values are shown and the reader is 
advised to interpret results conservatively.
Results
Eligibility Testing and Trial Entry
Of the 145 potentially medically eligible women screened by RPFNA, 66 were not tissue 
eligible. Of the 79 who were tissue eligible, 42 declined participation of which 28 entered 
another trial. Thus, 36 entered the trial for an acceptance rate if medically and tissue 
biomarker eligible of 46% close to the feasibility target rate of 50% (Supplementary Figure 
1). When it became apparent that completion rate and evaluability rate were high, accrual 
was stopped at 36 entrants as our target was 30 women with available blood and tissue pre 
and post treatment.
Baseline Demographics and Risk Factors
Median age was 44.5 (range 32-52) and all were premenopausal. Eleven of the 36 women 
(31%) were on oral contraceptives at baseline and throughout the trial. Ninety-seven percent 
of participants self-identified as non-Hispanic white; and 3% as African-American. Eighty-
three percent of participants were college graduates, and 47% had postgraduate degrees. 
Median BMI was 25.0 kg/m2 (range 17.0 - 34.7 kg/m2), 25% were obese (BMI 30 kg/m2 or 
higher). Eighty-three percent had a positive family history of breast cancer, 25% had a prior 
precancerous biopsy showing atypical hyperplasia, LCIS or DCIS and 47% had an estimated 
mammographic density of >50%. (Supplementary Table 1).
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Retention, Compliance, Adverse Events, and Quality of Life
Of the 36 women who enrolled, 34 (94%) completed the intervention and had a repeat 
RPFNA and at least 85% remaining on study were compliant with study medication. Thirty-
three of the 34 women who completed the study took 70% or more of prescribed drug, based 
on duration on drug (median 190 days, range 121-235 days) and returned pill counts.
A favorable side effect profile was also documented. Of the 40 Grade 2 or worse adverse 
events self-reported in 14 participants, only one (easy bruising) was characterized as 
probably due to study agent. Two subjects went off study early due to grade 1 
gastrointestinal symptoms. There were no clinically significant changes in electrolytes or 
liver or renal function. The median BCPT quality of life score was 7.5 at on-study (range 
0-29) and 7.0 at off-study (range 0-32). Higher scores denote greater symptoms.
Dietary Intake of Omega-3 and Omega-6 Fatty Acids
At baseline, the median dietary estimated combined EPA + DHA intake as assessed by the 
food frequency questionnaire was 90 mg/day with a similar amount for AA. Median intakes 
of the shorter chain omega 3 ALA and omega-6 LA were 1.0 g and 9.8 g, respectively. The 
median ratio of total omega-3: omega-6 fatty acids consumed at baseline was approximately 
1:10. There were no changes in dietary intake of EPA, DHA, AA or total omega-3 or 
omega-6 fatty acids over the course of the study.
Fatty Acid Profiles in Blood and Breast Aspirates
When assessed within 24 hours after the last dose, there was a decrease in AA, an increase 
in erythrocyte phospholipid EPA + DHA; resulting in a median 178% increase in (EPA
+DHA):AA ratio (Table 1). Participant blood samples for fatty acid analysis were also 
collected at RPFNA, a median of 21 days after drug discontinuation. Median erythrocyte 
phospholipid (EPA+DHA): AA ratio at 21 days after drug discontinuation declined to a 
value of 117% over baseline (see Supplemental Table 2). Change in plasma phospholipid 
and triacylglyceride were similar to those observed in erythrocyte phospholipids, except for 
a more rapid decline in (EPA+DHA): AA in plasma phospholipids after study agent 
discontinuation.
Although proportional amounts of fatty acids in breast aspirates were 8-40 fold lower than in 
erythrocytes or plasma, the baseline (EPA+DHA):AA ratios were in the same range (Table 
1). There was a decided effect of supplementation on breast triacylgylcerides with a median 
increase of 96% for the (EPA+DHA): AA ratio and 88% of participants exhibiting an 
increase (p<0.001) (Figure 1).
The above observations are consistent with omega-3 pharmacokinetics in which the half-life 
of EPA in serum triglycerides is 5-7 days, 1 month for erythrocyte phospholipids, and 6 
months to a year for adipose; with incorporation and washout generally longer for 
membrane phospholipids than for triacylgylcerides, and DHA longer than EPA [39].
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At baseline, median BMI was 25.0 kg/m2, body fat 39.7%, android fat 43.3%, waist 
circumference 85 cm, and waist hip ratio 0.81. There was a statistically significant change 
for waist circumference (median decrease of 2 cm; p=0.0091) and the corresponding waist 
to hip ratio (median decrease of 3%; p=0.014) (Supplemental Table 3).
Serum Hormones, Serum and Tissue Adipokines and Cytokines
There were no statistically significant changes in serum levels of bioavailable estradiol, or 
testosterone, progesterone, high sensitivity CRP, high molecular weight adiponectin, leptin, 
insulin, TNF-α, resistin, PAI-I, HGF, NGF, and MCP-1 (Table 2). Glucose, insulin, HOMA 
IR, HOMA %S, and HOMA %B showed no significant changes although a numerical 
increase (improvement) was observed for HOMA % B (Table 2). Although 33 paired 
RPFNA samples were available for adipocytokines, seven were omitted as due to visual 
blood contamination resulting in 25 paired specimens for tissue adipocytokines. No 
differences were noted in tissue cytokines except for a small but significant increase (61%; 
p=0.015) in TNF-α (Supplementary Table 4).
Cytomorphology, Ki-67, Mammographic Density
The off-study RPFNA was obtained a median of 21 days (range 5-78 days) after drug 
discontinuation. Favorable modulation was observed for the Masood cytomorphology index 
score, decreasing from a median of 15 at baseline to 14 after intervention (p<0.001) Table 
3). A decrease in Masood score was observed in 23 women versus an increase in 6 
(p<0.001) (Figure 2a). There was also a significant change in the designation of cytologic 
atypia, decreasing from 77% to 38% (p=0.0024). For all 34 women, Ki-67 decreased from a 
median of 2.1% at baseline to 1.0% off-study, with 23 decreasing versus 6 increasing 
(p=0.021) (Figure 2b). Mammographic breast density which was a median of 17% at 
baseline showed a modest median decrease in absolute density of -1.9% (relative value of 
-17%) with an average of 10 months between mammograms.
Benign Breast Tissue Gene Expression (mRNA)
No change was observed for 32 mRNA transcripts assessed in 29 pairs of frozen specimens, 
following normalization to reference transcripts. (Supplementary Table 5).
Benign Breast Tissue Proteomics (RPPA)
Results from 23 paired pre- and post-intervention RPFNA samples were available from 
Reverse Phase Protein Array (RPPA) for a set of 161 proteins and phosphoproteins. 
Restricting analysis to only 16 women with non-bloody paired samples, changes at the p<.05 
level were observed for 24 of 110 validated peptides and phosphopeptides (Table 4). A 
complete listing of all peptides assessed, plus analysis including bloody specimens, is 
available in Supplementary Table 6. Changes significant at the p<0.01 level were decreases 
in Bcl-2, eukaryotic initiation factor 4E (EIF4E), fibronectin, progesterone receptor (PgR), 
phosphorylated proline-rich Akt substrate (PRAS40_pT246), regulatory associated protein 
of mTOR (Raptor), stearoyl-CoA desaturase, and Smad3; and increases in 4E binding 
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protein 1 (4E-BP1) phosphorylated at threonine 37 and 46, protein kinase C alpha (PKC 
alpha), and tuberous sclerosis 2 protein (tuberin) phosphorylated at threonine 1462.
Discussion
Our single arm pilot study suggests the feasibility of assessing high dose omega-3 ethyl 
esters effects on risk biomarkers in larger placebo controlled Phase IIB trial. Uptake by 
potentially eligible premenopausal women was reasonable (46%) especially considering a 
competing trial. Side effects were minimal with excellent completion (94%) and compliance 
(85%) rates. Importantly it appeared that the 3-fold increase in the ratio of erythrocyte 
combined EPA + DHA to AA is associated with change in some breast tissue risk and 
mechanism of action biomarkers, although confirmation is needed in a placebo controlled 
trial. The primary endpoint for the IIB trial would likely be Ki-67 given the observed 
reduction in median Ki-67 from 2% at baseline to 1% at conclusion, despite lack of change 
in bioavailable hormones. Cross-sectional and prospective studies in women undergoing 
diagnostic breast biopsies suggest that women with hyperplasia +/- atypia with a Ki-67 of 
2% or higher have an increased short term risk of breast cancer [40,41]. The observed 
change in Ki-67 while not definitive due to lack of a placebo, permits us to both select a 
primary endpoint biomarker and determine a likely sample size of ~ 50 women per arm if 
care is taken to make the cohort as homogenous as possible presuming a minimum baseline 
of 1.5-2%.
Baseline EPA and DHA intakes were only 90 mg per day similar to average US intake and 
that in our cross sectional study of high risk women [10, 23]. Despite the marked increase in 
blood EPA plus DHA to AA ratio, we found no change in blood pro-inflammatory 
adipocytokines, a similar result to that reported by Yee et al. in a dose escalation trial [25]. 
Those supplementation studies of EPA + DHA in which change was observed in blood 
inflammatory markers used either cohorts with baseline evidence of systemic inflammation 
or assayed cytokines following monocyte activation with lipopolysaccharide [42]. We found 
only a median 1.7% absolute reduction in the risk biomarker mammographic density over 
the short study period. Whether this was due to the omega-3 supplementation, aging [43], or 
chance cannot be ascertained since there was no placebo group. A recent cross sectional 
study did not find an association between erythrocyte fatty acid composition and 
mammographic density [44].
We found no effect of EPA and DHA on 32 mRNA transcripts in benign breast tissue of a 
number of genes of interest including those involved in estrogen signaling, proliferation, and 
inflammation. This is not surprising as the activity of EPA and DHA is likely to be 
translational or post-translational in nature, with alteration of protein spatial location in lipid 
rafts and inhibition of compartmental translocation [17].
The breast tissue reverse phase proteomics assay was exploratory with the primary objective 
of identifying likely mechanisms of action. Given the large number of assays increasing the 
chance of a false positive, changes we observed are hypothesis generating only. However, 
similar to findings in preclinical models, EPA and DHA ethyl ester supplementation was 
observed to decrease cyclin D1 and bcl2 which are downstream from NFκB and AKT. This 
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suggests a decrease in NFkB nuclear translocation impairing nuclear signaling [16, 44]. 
Whether this might be due in turn to a reduction in eicosanoid intermediates (we did not 
measure) or changes in lipid raft structure is uncertain. Reduction in cyclin D1 and 
phosphorylated PED/PEA15 along with decreases in intermediates active in cytokine and 
growth factor signaling (STAT 5 and SMAD3), are consistent with reduction in proliferation 
[45-47]. Decreases were also observed in progesterone receptor associated with estrogen 
related signaling and matrix associated proteins implicated in epithelial-mesenchymal 
transition (EMT) such as the adhesion related protein fibronectin and a phosphorylated 
myosin related protein myosin IIa [48].
However, changes in proteins associated with AKT/mTOR were mixed, possibly the result 
of omega-3 fatty acid induced increases in insulin signaling/sensitivity after an amino acid 
load as (RPFNAs were performed after a meal) combined with inhibition of some aspects of 
AKT/mTOR pro-oncogenic signaling. We observed increases in pPDK1, pAKT, pTSC2, 
eEF2K, and pE-BP1, suggesting a permissive effect on mTORC1 and an increase in protein 
synthesis. Absence of an increase in p70S6K, 4EBP1 phosphorylated at serine 65, or 
phosphorylated S6 suggest lack of strong oncogenic activity [49-51]. In fact, the observed 
decreases in eIF4E and several other proteins necessary for mTOR signaling such as Raptor, 
PRAS40, cyclin D1, and stearoyl CoA desaturase (SCD) a key enzyme in fatty acid 
synthesis, suggest reduction in mTOR-associated cell proliferation and growth [52,53]. A 
mixed effect pattern with failure of DHA to block PDK1 phosphorylation of AKT despite 
reduction in mammary carcinogenesis has previously been observed in preclinical models 
[15].
In summary, EPA plus DHA ethyl esters in a total dose of 3.4 g per day for 6 months 
resulted in a significant increase in the EPA+DHA: AA ratio in blood and benign breast 
tissue. We observed a reduction in benign breast epithelial proliferation (Ki-67) and the 
frequency of cytologic evidence of atypia, concomitant with change in a number of breast 
proteins of which several have previously been identified as important in breast 
carcinogenesis. Although these single arm pilot results must be viewed with caution and 
modulation of risk and mechanism of action biomarkers confirmed, the 46% uptake and 
excellent completion (94%) and compliance (85%) rates suggest that a Phase II B placebo-
controlled trial is feasible.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Changes in the ratio of (EPA+DHA):AA in the breast triacylglyceride compartment. 
Baseline aspiration values are shown on the x-axis; repeat aspiration on the y-axis. The line 
represents no change in value; symbols above the line denote an increase and symbols below 
the line a decrease. P-value via Wilcoxon signed rank test.
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Panel A: Change in semi-quantitative Masood cytology index score over the course of the 
intervention. Baseline aspiration values are shown on the x-axis; repeat aspiration on the y-
axis. The line represents no change in value; symbols above the line denote an increase and 
symbols below the line a decrease. P-value via Wilcoxon signed rank test.
Panel B: Change in Ki-67 expression (percent of cells staining positive) over the course of 
the intervention. Baseline aspiration values are shown on the x-axis; repeat aspiration on the 
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y-axis. The line represents no change in value; symbols above the line denote an increase 
and symbols below the line a decrease. P-value via Wilcoxon signed rank test.
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Table 1
Change in fatty acid content for the 34 subjects who completed the trial. Erythrocyte Phosholipids (PLs), 
Plasma PLs and Triacylglycerides (TAGs), and Breast Aspirate PLs and TAGs.
Tissue /Lipid Compartment Fatty 
Acid Component
Median Values
P-Value (Wilcoxon) for 
Baseline to FNA2
Percent of total fatty acid content
Relative Change 




Erythrocyte PLs N=34 N=34 N=32 N=32
AA 12.8 10.7 10.8 −16% <0.001
EPA 0.40 2.24 1.27 235% <0.001
DHA 2.95 5.46 4.71 64% <0.001
EPA+DHA:AA Ratio 0.27 0.76 0.56 117% <0.001
Plasma PLs N=34 N=34 N=32 N=32
AA 9.9 8.2 8.6 −11% <0.001
EPA 0.54 2.80 0.64 30% 0.0013
DHA 2.50 4.50 3.35 37% <0.001
EPA+DHA:AA Ratio 0.30 0.91 0.45 44% <0.001
Plasma TAGs N=34 N=34 N=31 N=31
AA 1.58 1.44 1.50 −10% 0.29
EPA 0.18 1.02 0.24 28% 0.017
DHA 0.47 1.94 0.67 61% <0.001
EPA+DHA:AA Ratio 0.38 1.97 0.73 49% <0.001
Breast TAGs N=32 N=32 N=32
AA 0.32 0.34 6.5% 0.47
EPA 0.033 0.096 165% <0.001
DHA 0.073 0.147 42% <0.001
EPA+DHA:AA Ratio 0.29 0.51 96% <0.001
Breast PLs N=33 N=33 N=33
AA 0.65 0.57 2.9% 0.54
EPA 0.051 0.049 21% 0.30
DHA 0.129 0.149 18% 0.16
EPA+DHA:AA Ratio 0.23 0.32 35% 0.044
a
Blood collected within a day of scheduled discontinuation of drug, after a nominal 6 months of intervention.
b
Second blood specimen collected on the day of the second aspiration, a median of 21 days after scheduled drug discontinuation.
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Table 2
Change in serum biomarkers for 34 subjects who completed the trial.
Biomarker Median Pre-Study Median Post-Study Median Absolute Change Median Relative Change P-Value (Wilcoxon)
ELISA Methodology
High Molecular Weight 
Adiponectin, μg/ml
5.8 5.7 −0.09 −2% 0.73
hsCRP, μg/ml 1.4 1.2 −0.2 −23% 0.16
IGF-1, nM 18.5 16.7 0.4 3% 0.98
IGFBP3, nM 116 110 −4 −4% 0.080
IGF-1:IGFBP3 ratio 0.16 0.17 0.01 5% 0.20
SHBG, nM (with Estradiol) 114.5 112.6 2.5 5% 0.33
Estradiol, pg/ml 73.3 77.4 −10.5 −11%
0.13
Estradiol, pM 0.27 0.29 −0.4 −11%
Bioavailable Estradiol, pM 2.71 3.08 −0.31 −15% 0.13
Progesterone, ng/ml 0.90 0.97 −0.03 −4%
0.98
Progesterone, nM 2.9 3.1 −0.1 −4%
SHBG, nM (with Testosterone) 99.4 105.5 0.6 1% 0.86
Testosterone, ng/ml 0.55 0.46 −0.03 −5%
0.38
Testosterone, nM 1.88 1.60 −0.11 −5%
Bioavailable Testosterone, pM 16.6 16.5 −0.12 −2% 0.38
Luminex® Methodology
Adiponectin, μg/ml 17.0 18.4 −1.3 −8% 0.44
Leptin, ng/ml 12.3 12.3 1.2 9.4% 0.67
Adipo:Leptin Ratio 1170 1559 −36 −6% 0.37
HGF, pg/ml 264 240 −17 −8% 0.74
Insulin, pg/ml 168 140 −18 −9% 0.22
MCP-1, pg/ml 179 166 −7 −5% 0.21
NGF, pg/ml 5.9 5.5 −0.3 −6% 0.18
PAI-1, ng/ml 30.3 32.1 −0.8 −3% 0.97
Resistin, ng/ml 23.4 24.5 −0.8 −4% 0.54
TNF-α, pg/ml 2.7 2.8 0.0 0% 0.88
Assessment of Insulin Resistance
Glucose, mg/dL 95.0 93.0 −2.5 −3% 0.075
Immunoreactive Insulin, μU/ml 5.3 4.7 0.0 0% 0.55
Pro-Insulin 8.7 9.2 0.2 2% 0.89
HOMA2 %B 61.2 66.7 5.1 9% 0.13
HOMA2 %S 142.6 160.3 −0.1 0% 0.78
HOMA2 IR 0.7 0.6 0.0 0% 0.32
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Table 3
Change in risk and response biomarkers for 34 subjects who completed the trial.
Biomarker Median Pre-Study Median Post-Study Median Absolute Change Median Relative Change P-Value Wilcoxon (McNemar)
RPFNA Specimens











1-5 × 103 1-5 × 103 16 decrease
3 increase
0.0015









16.8 15.8 −1.9 −17% 0.0036
*
If omit one baseline specimen exhibiting 0% (not possible to decrease), then p=0.0091.
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Table 4
Significant (p<0.05) changes in levels of 26 peptides and phosphopeptides in RPFNA specimens, assessed by 
Reverse Phase Protein Array.
Protein (See Supplementary Table 
for Gene Name)
Antibody Name and specific 
phosphorylation site
Number of paired specimens 
where levels P-value (Wilcoxon 2-sided)
decrease increase
4E-BP1 4E-BP1_pS65 5 11 0.049
4E-BP1 4E-BP1_pT37_T46 4 12 0.0045
Akt Akt_pS473 3 13 0.039
Bcl-2 BCL2 13 3 0.0072
C-Raf C-Raf 13 3 0.039
Cyclin D1 Cyclin D1 11 5 0.044
Eukaryotic elongation factor 2 kinase eEF2K 4 12 0.011
Eukaryotic initiation factor 4E eIF4E 14 2 0.0016
Fibronectin Fibronectin 13 3 0.0052
GATA binding protein 3 GATA3 13 3 0.023
Her-3 HER3 13 3 0.011
Myosin isoform IIa Myosin IIa_pS1943 12 4 0.011
Phosphoinositide-dependent protein 
kinase 1
PDK1_pS241 4 12 0.049
Phosphoprotein Enriched in Diabetes/ 
Phosphoprotein Enriched in Astrocytes 
- 15 kDa
PED/PEA15_pS116 12 4 0.023
Protein Kinase c alpha PKC alpha 2 14 0.0038
Progesterone Receptor Progesterone Receptor 12 4 0.0027
Proline-Rich Akt Substrate PRAS40_pT246 13 3 0.0027
Regulatory associated protein of mTOR Raptor 13 3 0.0052
Rb Rb_pS807_S811 5 11 0.044
Stearoyl-CoA desaturase SCD 13 3 0.0045
Smad3 Smad3 14 2 0.0023
Src Src_pY627 3 13 0.017
Stat5a Stat5a 11 5 0.044
Spleen tyrosine kinase Syk 14 2 0.013
Transglutaminase II TGM2 11 5 0.044
Tuberin TSC2 Tuberin_pT1462 4 12 0.0061
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